Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026

Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究

Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划，推进神经退行性疾病血液生物标志物相关研究

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling

Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Alamar Biosciences Reports First Quarter 2026 Financial Results

Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference

Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026

Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ

Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ

Alamar Biosciences: Looking For An Early Detection

Alamar Biosciences valued at $1.5 billion as shares jump in Nasdaq debut